The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Apr 3

PMID 33810248

Citations 49

Authors

Francisco J Cueto

David Sancho

Affiliations

Soon will be listed here.

Abstract

Dendritic cells (DCs) prime anti-tumor T cell responses in tumor-draining lymph nodes and can restimulate T effector responses in the tumor site. Thus, in addition to unleashing T cell effector activity, current immunotherapies should be directed to boost DC function. Herein, we review the potential function of Flt3L as a tool for cancer immunotherapy. Flt3L is a growth factor that acts in Flt3-expressing multipotent progenitors and common lymphoid progenitors. Despite the broad expression of Flt3 in the hematopoietic progenitors, the main effect of the Flt3/Flt3L axis, revealed by the characterization of mice deficient in these genes, is the generation of conventional DCs (cDCs) and plasmacytoid DCs (pDCs). However, Flt3 signaling through PI3K and mTOR may also affect the function of mature DCs. We recapitulate the use of Flt3L in preclinical studies either as a single agent or in combination with other cancer therapies. We also analyze the use of Flt3L in clinical trials. The strong correlation between type 1 cDC (cDC1) infiltration of human cancers with overall survival in many cancer types suggests the potential use of Flt3L to boost expansion of this DC subset. However, this may need the combination of Flt3L with other immunomodulatory agents to boost cancer immunotherapy.

Citing Articles

Dendritic cell maturation in cancer.

Moon C, Belabed M, Park M, Mattiuz R, Puleston D, Merad M Nat Rev Cancer. 2025; .

PMID: 39920276 DOI: 10.1038/s41568-024-00787-3.

Conventional type 1 dendritic cells in the lymph nodes aggravate neuroinflammation after spinal cord injury by promoting CD8 T cell expansion.

Wang L, Wang X, Ma Y, Zhou H Mol Med. 2025; 31(1):37.

PMID: 39901071 PMC: 11789313. DOI: 10.1186/s10020-024-01059-4.

Cross-priming in cancer immunology and immunotherapy.

Luri-Rey C, Teijeira A, Wculek S, de Andrea C, Herrero C, Lopez-Janeiro A Nat Rev Cancer. 2025; .

PMID: 39881005 DOI: 10.1038/s41568-024-00785-5.

Developing an Effective Therapeutic HPV Vaccine to Eradicate Large Tumors by Genetically Fusing Xcl1 and Incorporating IL-9 as Molecular Adjuvants.

Sun Z, Wu Z, Su X Vaccines (Basel). 2025; 13(1).

PMID: 39852828 PMC: 11768903. DOI: 10.3390/vaccines13010049.

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E J Hematol Oncol. 2025; 18(1):6.

PMID: 39806516 PMC: 11733683. DOI: 10.1186/s13045-024-01634-6.

References

Enamorado M, Iborra S, Priego E, Cueto F, Quintana J, Martinez-Cano S . Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8 T cells. Nat Commun. 2017; 8:16073. PMC: 5520051. DOI: 10.1038/ncomms16073. View

Gilliland D, Griffin J . The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002; 100(5):1532-42. DOI: 10.1182/blood-2002-02-0492. View

Jojic V, Zuk O, Sun X, Best A, Knell J, Goldrath A . Identification of transcriptional regulators in the mouse immune system. Nat Immunol. 2013; 14(6):633-43. PMC: 3690947. DOI: 10.1038/ni.2587. View

Spranger S, Dai D, Horton B, Gajewski T . Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017; 31(5):711-723.e4. PMC: 5650691. DOI: 10.1016/j.ccell.2017.04.003. View

Tarhini A, Cherian J, Moschos S, Tawbi H, Shuai Y, Gooding W . Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol. 2011; 30(3):322-8. PMC: 3422533. DOI: 10.1200/JCO.2011.37.5394. View

CHAKRAVARTY P, Alfieri A, Thomas E, Beri V, Tanaka K, Vikram B . Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res. 2000; 59(24):6028-32. View

Baerenwaldt A, von Burg N, Kreuzaler M, Sitte S, Horvath E, Peter A . Flt3 Ligand Regulates the Development of Innate Lymphoid Cells in Fetal and Adult Mice. J Immunol. 2016; 196(6):2561-71. DOI: 10.4049/jimmunol.1501380. View

Helft J, Bottcher J, Chakravarty P, Zelenay S, Huotari J, Schraml B . GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells. Immunity. 2015; 42(6):1197-211. DOI: 10.1016/j.immuni.2015.05.018. View

Aspord C, Leccia M, Charles J, Plumas J . Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL. Cancer Immunol Res. 2014; 1(6):402-15. DOI: 10.1158/2326-6066.CIR-13-0114-T. View

10.

Li H, Yang C, Nallaparaju K, Zhang H, Liu Y, Goldrath A . The signal transducers STAT5 and STAT3 control expression of Id2 and E2-2 during dendritic cell development. Blood. 2012; 120(22):4363-73. PMC: 3507145. DOI: 10.1182/blood-2012-07-441311. View

11.

Bhardwaj N, Friedlander P, Pavlick A, Ernstoff M, Gastman B, Hanks B . Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. Nat Cancer. 2022; 1(12):1204-1217. DOI: 10.1038/s43018-020-00143-y. View

12.

Theisen D, Ferris S, Briseno C, Kretzer N, Iwata A, Murphy K . -Dependent Genes Control Tumor Rejection Induced by Dendritic Cells Independently of Cross-Presentation. Cancer Immunol Res. 2018; 7(1):29-39. DOI: 10.1158/2326-6066.CIR-18-0138. View

13.

Hammerich L, Marron T, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S . Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019; 25(5):814-824. DOI: 10.1038/s41591-019-0410-x. View

14.

Banchereau J, Steinman R . Dendritic cells and the control of immunity. Nature. 1998; 392(6673):245-52. DOI: 10.1038/32588. View

15.

Stirewalt D, Radich J . The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003; 3(9):650-65. DOI: 10.1038/nrc1169. View

16.

Svensson M, Andersson K, Wasen C, Erlandsson M, Nurkkala-Karlsson M, Jonsson I . Murine germinal center B cells require functional Fms-like tyrosine kinase 3 signaling for IgG1 class-switch recombination. Proc Natl Acad Sci U S A. 2015; 112(48):E6644-53. PMC: 4672832. DOI: 10.1073/pnas.1514191112. View

17.

Brasel K, McKenna H, Morrissey P, Charrier K, Morris A, Lee C . Hematologic effects of flt3 ligand in vivo in mice. Blood. 1996; 88(6):2004-12. View

18.

Barry K, Hsu J, Broz M, Cueto F, Binnewies M, Combes A . A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018; 24(8):1178-1191. PMC: 6475503. DOI: 10.1038/s41591-018-0085-8. View

19.

Dosil M, Wang S, Lemischka I . Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol Cell Biol. 1993; 13(10):6572-85. PMC: 364716. DOI: 10.1128/mcb.13.10.6572-6585.1993. View

20.

Steinman R, Hawiger D, Nussenzweig M . Tolerogenic dendritic cells. Annu Rev Immunol. 2003; 21:685-711. DOI: 10.1146/annurev.immunol.21.120601.141040. View